Fact-checked by Grok 2 weeks ago

Necrotizing enterocolitis

Necrotizing enterocolitis () is a life-threatening acute inflammatory of the intestine that predominantly affects premature neonates, characterized by mucosal or transmural of the bowel wall, which may progress to , , and . The condition arises from a multifactorial interplay involving , bacterial overgrowth, and an immature gut barrier, leading to translocation of pathogens and exaggerated inflammatory responses. NEC most commonly manifests in infants born before 32 weeks gestation or weighing less than 1500 grams at birth, with incidence rates ranging from 5% to 10% among very low birth weight neonates admitted to neonatal intensive care units. Key risk factors include extreme prematurity, enteral feeding with formula rather than human , , and indwelling umbilical catheters, though the precise etiology remains incompletely understood despite extensive research. Clinical presentation typically involves nonspecific symptoms such as feeding intolerance, , bloody stools, and , with radiographic evidence of serving as a hallmark diagnostic feature. Management entails prompt cessation of enteral feeds, broad-spectrum antibiotics, and supportive care, with surgical resection indicated for or failed medical therapy; overall mortality approaches 20-50%, particularly in advanced stages, underscoring NEC as a leading cause of neonatal gastrointestinal morbidity and death.31714-7/fulltext)

Epidemiology

Incidence and Demographics

Necrotizing enterocolitis (NEC) has an overall incidence of 0.3 to 2.4 cases per 1,000 live births worldwide. , population-based data from 1999 to 2020 indicate an average rate due to NEC of 10.2 per 100,000 live births, with peaks around 13.2 per 100,000 in 2005 and a decline to 8.3 per 100,000 by 2020. The condition predominantly affects neonates, with nearly 90% of cases occurring in preterm infants born before 36 weeks gestation. Incidence rates escalate dramatically with decreasing and . Among very (VLBW) infants (<1,500 g), rates range from 5% to 10%, while in extremely low birth weight (ELBW) infants (<1,000 g), they can reach 13%. A large cohort study of 25,821 VLBW infants reported an overall NEC incidence of 8.8%, stable across study periods from 2010 to 2017. In contrast, term infants experience much lower rates, increasing from 0.16 to 0.71 per 1,000 live births in some regional analyses. Disease onset typically occurs between 27 and 34 weeks post-conceptional age. Demographically, NEC shows associations with racial and ethnic factors. Black infants exhibit trends toward higher rates of surgical NEC (36%) compared to Hispanic (33%) and White (34%) infants. Broader disparities indicate elevated incidence and morbidity in Black preterm populations, potentially linked to socioeconomic and perinatal factors, though causality remains under investigation. No consistent sex-based differences in incidence have been widely reported in large-scale studies. The condition accounts for up to 8% of neonatal intensive care unit admissions, underscoring its concentration in vulnerable neonatal cohorts. The incidence of necrotizing enterocolitis (NEC) exhibits significant geographic variation, primarily driven by differences in neonatal care capabilities, prematurity survival rates, and preventive practices across regions. Globally, among very low birth weight (VLBW) infants, the pooled incidence ranges from 2% to 13%, with a systematic review estimating approximately 7% overall, though heterogeneity between studies is high due to variations in diagnostic criteria and reporting. In high-resource settings with advanced neonatal intensive care units (NICUs), NEC rates are influenced by higher survival of extremely preterm infants, who bear the highest risk; for instance, rates as low as 2-4% have been reported in countries like , , and , attributed to widespread use of human milk feeding and standardized protocols. Conversely, in low- and middle-income countries, underreporting and limited access to diagnostics may underestimate true burden, but available data suggest comparable or higher rates in preterm cohorts where formula feeding predominates. Within the United States, geographic disparities align with regional differences in preterm birth rates and NICU quality; NEC-related infant mortality rates (NEC-IMR) vary by state, with higher burdens in the South and Midwest compared to the Northeast, potentially linked to socioeconomic factors and perinatal care access. Racial variations compound these trends, with Black infants experiencing persistently higher NEC-IMR than White infants (e.g., 1.5-2 times elevated in recent cohorts), independent of gestational age, suggesting contributions from unmeasured social determinants or genetic predispositions not fully explained by prematurity alone. Internationally, population-based registries in Europe, such as those in the Netherlands and Spain, report NEC incidences of 4-7% in VLBW infants, with lower figures in Scandinavian nations reflecting aggressive implementation of evidence-based prevention. Temporally, NEC incidence in preterm infants has shown mixed trends, with declines in some high-income settings offset by increases elsewhere due to rising survival of extremely preterm neonates. In the US, overall NEC incidence among VLBW infants decreased from 7.1% in 2005 to 5.2% by 2014, paralleling broader reductions in from a peak of 13.2 per 100,000 live births in 2005 to 8.3 in 2020, likely attributable to increased human milk usage, probiotic supplementation, and refined feeding guidelines. However, in Sweden, incidence rose among extremely preterm infants from 2004-2007 to 2014-2016 (from ~5% to higher rates), correlated with policy shifts toward active resuscitation of smaller gestations, highlighting how improved viability can inflate disease occurrence without proportional advances in prevention. Global data indicate stable or modestly declining rates in recent decades (e.g., ~7% in VLBW cohorts as of 2020), but contradictory reports underscore challenges in surveillance, with some clusters showing periodicity every 10 years unrelated to seasonal patterns. These shifts emphasize the impact of evolving neonatal practices, though persistent gaps in low-resource areas limit comprehensive trend analysis.

Pathophysiology

Core Mechanisms of Tissue Injury

Necrotizing enterocolitis (NEC) tissue injury primarily arises from intestinal ischemia, bacterial invasion, and an exaggerated inflammatory response in the immature neonatal gut. Ischemia, often precipitated by hypoxic events or splanchnic hypoperfusion, damages the intestinal mucosa, increasing permeability and allowing bacterial translocation across the epithelial barrier. Bacterial products, particularly lipopolysaccharide (LPS) from gram-negative pathogens, activate (TLR4) on enterocytes, which is overexpressed in premature infants. This signaling cascade induces enterocyte apoptosis and necroptosis, disrupting mucosal integrity and amplifying injury. The dysregulated innate immune response further exacerbates tissue damage through excessive production of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), as well as platelet-activating factor (PAF). These mediators promote endothelial dysfunction via TLR4 on mesenteric vessels, leading to vasoconstriction, impaired microcirculation, and secondary ischemia. Upregulation of inducible nitric oxide synthase (NOS-2) results in nitric oxide (NO) overproduction, contributing to cellular toxicity, vasodilation imbalance, and necrosis. Immature tight junctions and deficient mucin production compound barrier failure, facilitating ongoing bacterial penetration and systemic inflammation. Histopathologic progression includes submucosal edema, hemorrhage, coagulation necrosis, and gas cysts (pneumatosis intestinalis) from bacterial fermentation, culminating in full-thickness necrosis and potential perforation. Deficient counter-regulatory mechanisms, such as reduced IL-10 and transforming growth factor-β (TGF-β), fail to mitigate this inflammatory amplification in preterm neonates. Experimental models confirm that TLR4 deficiency or blockade prevents these downstream effects, underscoring the central role of microbial-immune crosstalk in driving necrotic injury.

Role of Gut Microbiome and Dysbiosis

The gut microbiome plays a central role in the pathogenesis of (NEC), particularly through dysbiosis characterized by reduced microbial diversity and shifts favoring proinflammatory taxa in preterm infants. In healthy term infants, the gut microbiota establishes a balanced community postnatally, but preterm neonates exhibit delayed colonization with lower alpha diversity and dominance by facultative anaerobes such as . This dysbiosis, often evident 1–3 weeks before NEC onset, involves enrichment of (e.g., Klebsiella pneumoniae, Escherichia coli) and depletion of protective and species, creating an environment conducive to exaggerated inflammatory responses. Dysbiosis precedes NEC in observational studies of preterm cohorts; for instance, a longitudinal analysis of 120 infants found Gammaproteobacteria enrichment in 46 who developed NEC across 2,720 stool samples, correlating with postmenstrual age and feeding patterns. Similarly, metagenomic sequencing in 160 preterm infants identified Klebsiella overgrowth and increased bacterial replication rates as predictors of disease, with Proteobacteria phylum dominance replacing typical anaerobic transitions. These shifts disrupt mucosal barrier integrity, as evidenced by animal models where germ-free mice are resistant to NEC-like injury, but colonization with dysbiotic preterm-derived microbiota induces TLR4-dependent epithelial cell death and ischemia. The causal link involves dysbiotic taxa stimulating innate immune overactivation via pattern recognition receptors like , leading to cytokine storms (e.g., , ), reduced mucin production, and impaired tight junction function, culminating in translocation of pathogens and necrosis. NEC's postnatal exclusivity underscores this, as the sterile intrauterine environment precludes microbial involvement, with disease emerging only after vaginal or cesarean delivery introduces initial colonizers. Meta-analyses confirm consistent pre-NEC signatures of low and high across studies, though variability exists due to confounders like antibiotic exposure. Therapeutic modulation of the microbiome shows promise; randomized trials of probiotics (e.g., ) reduce NEC incidence by 50–70% in very low birth weight infants by restoring diversity and enhancing barrier function, outperforming formula feeding alone. Breast milk, rich in oligosaccharides that promote growth, lowers risk compared to bovine-based formulas, supporting microbiota maturation. However, causality remains associative in humans, with ongoing needs for multi-omics to refine predictive biomarkers and avoid overgeneralization from rodent models.

Risk Factors

Prematurity and Neonatal Vulnerabilities

Prematurity represents the most significant risk factor for (NEC), with over 90% of cases occurring in infants born before 37 weeks' gestation. The incidence of NEC rises sharply with decreasing gestational age, reaching approximately 7% among extremely preterm infants born between 22 and 28 weeks. In neonates under 32 weeks' gestation, the rate of severe NEC is about 3.15%, while studies report incidences up to 7.8% in those born before 29 weeks. Low birth weight, often correlated with prematurity, further amplifies vulnerability, with mean gestational ages of NEC-affected infants around 27.5 weeks and birth weights near 1,044 grams. Neonatal gut immaturity underlies this susceptibility, featuring an underdeveloped intestinal epithelial barrier with heightened permeability that facilitates bacterial translocation and invasion. Premature infants exhibit reduced mucosal defense mechanisms, including lower gastric acidity and immature innate immunity, which impair pathogen clearance and increase the risk of inflammatory cascades triggered by gut dysbiosis. Additionally, underdeveloped gastrointestinal motility and peristalsis contribute to stasis, promoting bacterial overgrowth, while systemic immaturities—such as fragile respiratory and cardiac function—heighten sensitivity to hypoxia, reducing intestinal perfusion and exacerbating tissue injury. These vulnerabilities are compounded by small-for-gestational-age status and associated conditions like respiratory distress, which collectively impair adaptive responses to enteral feeding challenges common in neonatal intensive care. Empirical data from cohort studies consistently link earlier gestational ages to poorer outcomes, with NEC mortality in extremely low birth weight infants (<1,000 grams) ranging from 40% to 100%, underscoring the causal primacy of developmental immaturity over secondary factors. Enteral feeding with bovine milk-based formula, rather than human milk, significantly elevates the risk of necrotizing enterocolitis (NEC) in preterm infants. A randomized controlled trial in very low birth weight infants found that exclusive human milk feeding reduced NEC odds by 77% compared to bovine formula (OR 0.23, 95% CI 0.08-0.66). Meta-analyses confirm this protective effect, with human milk yielding a relative risk reduction of NEC to 0.62 (95% CI 0.42-0.93) versus formula. Mother's own milk offers superior protection over donor human milk, which in turn lowers NEC incidence compared to formula (RR 4.62, 95% CI 1.47-14.56 for formula versus donor milk). Feeding practices, including the timing and rate of enteral nutrition advancement, have been investigated as potential modifiable risks. Observational data indicate that rapid volume increases exceeding 20-30 mL/kg/day may correlate with higher NEC incidence in preterm infants. However, randomized trials, such as a 2019 multicenter study comparing 30 mL/kg/day versus 20 mL/kg/day advancements, found no significant increase in NEC with faster rates and suggested possible reductions in related outcomes like mortality and sepsis. Trophic (minimal) enteral feeding durations also influence risk, with evidence suggesting that extended periods before full advancement do not clearly mitigate and may prolong time to full feeds without added benefit. Short trophic phases (e.g., 1-3 days) show no elevated risk compared to longer ones in underpowered studies, while early initiation of trophic feeds with human milk is associated with overall lower rates in very low birth weight infants. These findings underscore that while formula avoidance is a robust risk mitigator, optimal advancement protocols remain informed by balancing prevention against nutritional delays.

Maternal, Perinatal, and Iatrogenic Factors

Maternal factors contributing to (NEC) risk in neonates include , , and (IUGR), often linked to and chronic fetal hypoxia. A case-control study identified higher maternal prevalence of (odds ratio 2.5), clinical , and acute amnionitis among NEC cases compared to controls, with these conditions potentially promoting fetal inflammatory responses that sensitize the immature gut. and have also been associated in meta-analyses, though evidence strength varies due to confounding by prematurity. Perinatal factors encompass events surrounding delivery, such as birth asphyxia, fetal distress, and cesarean section, which may exacerbate gut ischemia-reperfusion injury in vulnerable preterm infants. Neonatal asphyxia independently predicts NEC development, with hypoxia-ischemia disrupting intestinal barrier integrity and promoting bacterial translocation. Cesarean delivery, observed in up to 70% of NEC cases in some cohorts, correlates with delayed microbiome colonization and increased formula feeding reliance, though causality remains debated amid selection bias for high-risk births. Premature rupture of membranes and placental abnormalities further heighten risk by facilitating intrauterine infection. Iatrogenic factors primarily involve red blood cell (RBC) transfusions and prolonged antibiotic exposure, which can induce gut dysbiosis and inflammatory cascades. Transfusion-associated NEC occurs in 2-5% of exposed very low birth weight infants, with studies showing adjusted odds ratios of 1.6-5.2 for NEC post-transfusion, potentially due to bioactive lipids in stored blood triggering mucosal injury. Early or extended empiric antibiotics (>5 days) elevate NEC risk by 2-4 fold in preterm cohorts, as they suppress commensal flora, fostering pathogenic overgrowth like or . These interventions, while necessary for sepsis prevention, underscore the need for judicious use to mitigate secondary gut vulnerability.

Clinical Presentation

Early Signs and Symptoms

The early clinical presentation of necrotizing enterocolitis (NEC) in neonates is often nonspecific and insidious, frequently overlapping with other gastrointestinal or systemic disturbances in premature infants, typically emerging days to weeks after birth following enteral feeding initiation. Initial symptoms center on gastrointestinal dysfunction, including feeding intolerance manifested as emesis, refusal to feed, or elevated gastric residuals, which reflect impaired intestinal and absorption. Abdominal distention represents a hallmark early sign, resulting from or gas accumulation, often accompanied by mild tenderness on palpation, reduced bowel sounds, or visible peristaltic loops; discoloration or of the may also occur. Systemic indicators include lethargy or decreased activity, thermal instability ( or ), apnea episodes, , and occasionally , signaling early metabolic and autonomic derangements. Hematochezia or occult blood in stools (guaiac-positive) can appear as an early gastrointestinal symptom, though it is less consistent initially compared to feeding issues and may indicate mucosal injury; diarrhea with altered stool consistency is also reported but remains nonspecific. These findings prompt heightened monitoring in neonatal intensive care units, as progression to fulminant disease can occur rapidly within hours if unrecognized, underscoring the need for serial abdominal examinations and vital sign assessments.

Disease Staging and Progression

The Modified Bell staging criteria, an expansion of the original 1978 , classify necrotizing enterocolitis (NEC) based on clinical findings, radiographic evidence, and laboratory or systemic manifestations to assess disease severity and inform management decisions. This system divides NEC into suspected ( I), definite ( II), and advanced ( III) categories, with sub-stages reflecting escalating involvement of intestinal necrosis and systemic compromise. Staging correlates with outcomes, as higher stages indicate greater risk of perforation, , and mortality rates exceeding 50% in III cases.
StageSub-stageClinical FeaturesRadiographic FindingsLaboratory/Systemic Signs
I (Suspected NEC)IATemperature instability, apnea, , , poor feeding, emesis, abdominal distentionIntestinal or fixed loops; mild Unremarkable or nonspecific; stable blood gases and platelets
I (Suspected NEC)IBAs in IA, plus grossly stoolsAs in IAAs in IA
II (Definite NEC)IIA (Mildly ill)As in I, plus absent bowel sounds, right upper quadrant mass/induration; portal vein gas uncommonMild ; mild
II (Definite NEC)IIB (Moderately ill)As in IIA, plus worsening abdominal tendernessAs in IIA, plus persistent As in IIA, plus worsening , , or
III (Advanced NEC)IIIA (Severely ill, no perforation)As in II, plus , As in II, plus or gasless abdomenAs in IIB, plus profound and instability
III (Advanced NEC)IIIB (Perforation)As in IIIA, plus As in IIIA, plus (free air)As in IIIA
Disease progression in NEC often begins insidiously with Stage I nonspecific gastrointestinal symptoms in preterm infants, advancing to in Stage II within 24 to 72 hours if untreated, reflecting gas formation from bacterial fermentation in ischemic mucosa. From Stage II, rapid deterioration to Stage III can occur in as few as 12 to 48 hours, driven by transmural , bowel , and secondary , with portal venous gas or free intraperitoneal air signaling imminent . Progression is not uniform; approximately 20-30% of suspected cases (Stage I) resolve without advancement, while definitive cases frequently escalate due to multifocal involvement of the terminal and colon. Early radiographic surveillance is critical, as clinical signs alone underestimate severity in up to 40% of cases progressing to .

Diagnosis

Clinical Assessment

Clinical assessment of necrotizing enterocolitis (NEC) begins with a high index of suspicion in preterm infants, particularly those born before weeks , who present with nonspecific gastrointestinal and systemic symptoms typically in the second to third week of life. Key historical features include feeding intolerance, emesis, , apnea, , and passage of bloody stools, often following initiation or advancement of enteral feeds. These signs reflect underlying and but lack specificity, necessitating prompt evaluation to differentiate from or other neonatal emergencies. Physical examination focuses on abdominal findings, which may include progressive distension, tenderness to , visible or intestinal loops, hypoactive bowel sounds, of the abdominal wall, and, in advanced cases, a palpable mass or guarding suggestive of . Systemic instability, such as temperature lability, , or respiratory distress, often accompanies these local signs, indicating potential or . The Bell staging system integrates these clinical elements: stage I (suspected NEC) features mild systemic manifestations like apnea, , or guaiac-positive stools without radiographic confirmation, while stage II incorporates worsening abdominal signs with laboratory derangements. Initial laboratory tests support clinical suspicion but are not diagnostic alone. often reveals (<150,000/µL) or leukopenia (<1,500/µL), signaling sepsis or bone marrow suppression, while C-reactive protein may be elevated. Blood gas analysis frequently shows metabolic acidosis and hyponatremia due to third-spacing or ileus, and a basic metabolic panel assesses electrolyte shifts. Blood and urine cultures are obtained to evaluate for concurrent infection, though yields are low; stool studies for occult blood confirm guaiac positivity but add limited value. Coagulation studies screen for disseminated intravascular coagulation in severe cases. These findings guide escalation to imaging and empiric antibiotics, with multidisciplinary input essential for timely intervention.

Diagnostic Imaging and Biomarkers

Abdominal radiography serves as the primary imaging modality for diagnosing (NEC), with serial supine and left lateral decubitus views recommended to detect evolving abnormalities. Characteristic findings include pneumatosis intestinalis, appearing as linear or cystic gas within the bowel wall, observed in approximately 50-75% of confirmed cases and considered highly specific when present. Additional signs encompass fixed dilated bowel loops, portal venous gas (indicating advanced ischemia), and free intraperitoneal air signaling perforation, which occurs in up to 20-30% of severe cases and necessitates urgent surgical evaluation. Point-of-care ultrasound (POCUS) has emerged as a valuable adjunct to radiography, offering radiation-free serial assessment of bowel wall thickness (typically >3 mm suggesting or ischemia), hyperemia on Doppler, absent , or echogenic free fluid indicative of . Studies demonstrate ultrasound sensitivity for NEC-specific features exceeding 90% in some cohorts, particularly for detecting portal gas or bowel wall abnormalities missed on , though operator dependence and lack of limit routine adoption. Contrast-enhanced ultrasound and advanced techniques like are investigational for non-invasive biomarker detection but remain preclinical. No single reliably diagnoses in isolation, as current options lack sufficient specificity and sensitivity amid confounding neonatal conditions like or feeding intolerance; multi-omics approaches integrating and are under exploration to address this gap. Intestinal fatty acid-binding protein (I-FABP), released from damaged enterocytes, shows promise as an early marker of gut ischemia, with or urinary levels elevated 24-48 hours before radiographic changes in stage II/III , achieving sensitivities of 70-90% in prospective studies. C-reactive protein (CRP) and (PCT) reflect systemic but are non-specific, with CRP rising >10 mg/L in most cases yet also elevated in non-NEC infections; serial CRP trends (e.g., failure to normalize after 48-72 hours of therapy) aid in monitoring progression or treatment response rather than initial . Stool biomarkers such as calprotectin (indicating mucosal ) and cytokines (e.g., IL-6, IL-8) correlate with disease severity but require validation for clinical use, as levels overlap with physiologic gut maturation in preterm infants. Emerging urinary markers like or trefoil factor 3 (TFF3) may enhance prognostic accuracy when combined with I-FABP, but prospective trials are needed to establish thresholds.

Prevention

Evidence-Based Prophylactic Strategies

Human milk feeding represents the most robust evidence-based strategy for preventing necrotizing enterocolitis (NEC) in preterm infants, with meta-analyses demonstrating a dose-dependent reduction in incidence. Exclusive or predominant feeding with mother's own milk lowers NEC risk compared to formula, attributed to bioactive components like oligosaccharides and immunoglobulins that support gut barrier integrity and microbiota modulation. Studies show that infants receiving over 50% of feeds as human milk have significantly reduced odds of NEC, with donor human milk also conferring protection when mother's milk is unavailable, particularly when fortified appropriately. Probiotic supplementation, particularly with and species or mixtures, has been shown in multiple randomized controlled trials to decrease incidence in very preterm or very infants. A 2023 Cochrane review of 57 trials involving 10,918 infants reported a (RR) of 0.54 (95% CI 0.46-0.65) for (bell stage II or higher) with versus placebo or no treatment, alongside reduced all-cause mortality. Network meta-analyses indicate superior efficacy for multi-strain combinations including , , and , though benefits may be less pronounced in extremely preterm infants (<28 weeks gestation), with ongoing concerns about strain-specific safety and sepsis risks from contaminated products. Guidelines increasingly endorse routine use in units with adequate quality control, but evidence quality varies due to heterogeneity in preparations and populations. Antenatal corticosteroid administration to mothers at risk of preterm delivery reduces neonatal incidence by promoting fetal gut maturation and reducing inflammation. Observational and experimental data, including rat models, demonstrate significant decreases in severity following a single course, with clinical studies supporting lower rates in exposed versus unexposed preterm cohorts. This intervention, standard for gestations 24-34 weeks, aligns with broader reductions in respiratory distress and intraventricular hemorrhage, though optimal timing and repeat dosing require further clarification. Additional strategies with supportive but less definitive evidence include standardized feeding protocols to avoid rapid advancement or hyperosmolar feeds, which minimize gut ischemia risks, and minimizing perinatal antibiotic exposure to preserve microbiota diversity. Prophylactic antibiotics lack efficacy and may increase resistance, per meta-analyses. Emerging approaches like erythropoietin for anemia prevention and acid suppression avoidance show promise in reducing transfusion-related and motility-disrupted NEC cases, but require larger trials for confirmation.

Nutritional Interventions

Exclusive human milk feeding significantly reduces the incidence of necrotizing enterocolitis (NEC) in preterm infants compared to formula feeding, with a meta-analysis of randomized controlled trials reporting a relative risk (RR) of 0.62 (95% CI 0.42-0.93). This protective effect is attributed to bioactive components in human milk, such as immunoglobulins, lactoferrin, and oligosaccharides, which support gut maturation and microbiome stability without direct causal proof from first-principles trials. Dose-response analyses indicate that higher proportions of human milk intake—ideally exclusive or near-exclusive—correlate with progressively lower NEC rates, with one meta-analysis showing reduced risk even at partial supplementation levels exceeding 50% of feeds. When maternal human milk is unavailable, donor human milk serves as a preferable alternative to preterm formula, lowering NEC risk by up to 2.77-fold in low-birth-weight infants per Cochrane review meta-analysis of nine trials, though nutritional adequacy requires fortification to meet growth needs. Bovine milk-based formulas, by contrast, are associated with elevated NEC incidence relative to any human milk exposure, as evidenced by comparative studies in very low-birth-weight infants, potentially due to differences in protein composition and osmolarity disrupting immature intestinal barriers. Guidelines from bodies like the American Academy of Pediatrics emphasize prioritizing human milk, including pasteurized donor sources, over formula to mitigate this risk, though long-term randomized data isolating formula as a direct cause remain limited. Enteral feeding protocols incorporating trophic (minimal) feeds—typically 10-20 mL/kg/day initiated within 24-96 hours of birth—have been linked to reduced NEC incidence in very low-birth-weight infants, with cohort studies showing decreased rates without increased complications when combined with gradual advancement. Evidence from systematic reviews supports early progressive enteral nutrition over withholding feeds, demonstrating no heightened NEC risk and potential benefits for gut adaptation, though slow volume advancement (e.g., ≤15-20 mL/kg/day increments) does not confer additional protection against NEC or mortality. Standardized protocols minimizing feeding interruptions and residuals further optimize outcomes, reducing NEC severity in implementation studies. Supplementation with prebiotics or synbiotics in feeds shows preliminary promise but lacks robust endorsement for routine use; a 2024 meta-analysis found synbiotics reduced all-stage NEC risk by 78% in very low-birth-weight neonates versus placebo, yet broader evidence prioritizes over additives due to inconsistent strain-specific efficacy and safety concerns like contamination. Arginine supplementation emerges as a targeted nutrient intervention in network meta-analyses, outperforming placebo in lowering NEC incidence, though integration into standard feeds requires further validation. Overall, nutritional strategies emphasize human milk-centric approaches, with feeding protocols tailored to preterm physiology for maximal risk reduction.

Treatment

Medical Management Protocols

Medical management of necrotizing enterocolitis (NEC) primarily targets Bell stage I or II disease, emphasizing bowel rest, broad-spectrum antibiotics, and supportive care to mitigate inflammation, prevent perforation, and promote resolution without surgery in approximately 50-75% of cases. Initial steps include immediate cessation of enteral feedings (NPO status) to reduce intestinal workload and gastric decompression via nasogastric or orogastric tube to minimize distension and vomiting. Concurrently, intravenous fluid resuscitation addresses hypovolemia or shock, with transition to total parenteral nutrition (TPN) for caloric support, typically providing 60-80 kcal/kg/day while monitoring glucose, electrolytes, and acid-base balance. Empiric intravenous antibiotics are administered promptly upon suspicion of NEC, targeting enteric pathogens including gram-negative aerobes, gram-positive cocci, and anaerobes; common regimens include ampicillin (100-200 mg/kg/day divided every 6-8 hours) plus gentamicin (5 mg/kg/day divided every 24-48 hours) with or without metronidazole (30 mg/kg/day divided every 6-8 hours) for anaerobic coverage. Therapy duration is generally 7-14 days, guided by clinical improvement, serial inflammatory markers (e.g., C-reactive protein normalization), and negative blood/stool cultures, with de-escalation if cultures remain sterile. Multidisciplinary monitoring involves frequent abdominal examinations, vital signs, complete blood counts, and serial abdominal radiographs every 6-12 hours to detect progression such as portal venous gas or free air, prompting surgical consultation regardless of stage. Supportive measures include respiratory support via mechanical ventilation if apnea or respiratory failure occurs, and hemodynamic stabilization with vasopressors for septic shock, as NEC often involves systemic inflammatory response syndrome. Blood product transfusions (e.g., packed red blood cells for anemia or platelets for thrombocytopenia) are administered judiciously to avoid exacerbating gut hypoxia, with thresholds like hemoglobin <10 g/dL or platelets <50,000/μL. Reintroduction of enteral feeds occurs cautiously after 7-14 days of stability, starting with trophic volumes (10-20 mL/kg/day) of human milk if available, advancing slowly over 7-10 days while monitoring residuals and stools. Failure to improve within 48-72 hours or worsening signs (e.g., rising lactate, persistent ileus) necessitate evaluation for surgical intervention. Protocols emphasize early pediatric surgery involvement and transfer to tertiary centers with neonatal intensive care capabilities.

Surgical Interventions and Timing

Surgical intervention is required in 20-50% of necrotizing enterocolitis (NEC) cases, primarily when medical management fails or complications such as intestinal perforation arise. Indications include radiographic evidence of pneumoperitoneum, portal venous gas persisting despite medical therapy, fixed dilated bowel loops, or clinical deterioration manifested by worsening sepsis, abdominal distension, or hemodynamic instability. The primary surgical approach is exploratory laparotomy, involving resection of necrotic bowel segments, assessment of remaining bowel viability, and either primary anastomosis or enterostomy formation, with stomas preferred in preterm infants to minimize anastomotic complications. Peritoneal drainage offers a minimally invasive bedside alternative, particularly for extremely low birth weight infants (<1000 g) deemed too unstable for laparotomy, by evacuating peritoneal fluid and decompressing the abdomen. However, randomized controlled trials, including the 2006 NET trial, demonstrate no significant mortality benefit for primary peritoneal drainage over laparotomy (relative risk 1.03; 95% CI 0.92-1.15), with drainage often necessitating subsequent laparotomy in up to 50% of cases. Some observational data suggest higher mortality with drainage (up to 55% excess risk), attributed to delayed definitive treatment of necrosis. Timing of surgery remains debated, with prompt intervention critical for perforation to prevent further sepsis and multi-organ failure, ideally within hours of definitive diagnosis. In non-perforated but medically refractory cases (), watchful waiting with serial assessments is standard, escalating to surgery upon trajectory of metabolic derangement or clinical worsening, as delays beyond 48 hours from deterioration may worsen outcomes, though early surgery in sicker patients correlates with higher short-term mortality due to selection bias. Prospective studies emphasize ultrasound-guided decision-making to refine timing, reducing unnecessary interventions while avoiding procrastination in progressive disease. Second-look laparotomies, performed 24-48 hours post-initial resection, are selectively used to reassess marginal bowel viability.

Prognosis

Mortality Rates and Immediate Outcomes

Necrotizing enterocolitis (NEC) carries significant mortality risk, particularly in preterm infants, with overall rates ranging from 20% to 50% across studies of confirmed cases (Bell stage II or higher). In a multicenter cohort of U.S. neonatal intensive care units from 2010 to 2018, in-hospital mortality was 23.5% for all infants with confirmed NEC, rising to 34.5% among those requiring surgical intervention. Rates escalate with decreasing gestational age and birth weight; for extremely low birth weight infants (<1000 g), mortality can reach 40-100%, driven by comorbidities like sepsis and multiorgan failure. In low- and middle-income countries, in-hospital mortality exceeds 70-80% among preterm or low birth weight neonates, reflecting disparities in access to advanced care such as timely surgery and ventilatory support. Surgical NEC, occurring in 20-40% of cases, portends worse immediate prognosis, with mortality 1.5-2 times higher than medical management alone due to complications like bowel and hemodynamic instability. Short-term survival to discharge hovers around 70-80% in high-resource settings for medically treated infants, but only 50-70% for surgical cases, often complicated by postoperative sepsis (affecting >50%) or prolonged dependency. Bell staging influences outcomes: stage I cases rarely fatal (<5%), while stage III (with ) mortality approaches 50%. Recent data indicate modest declines in NEC-attributable mortality in developed nations, with annual reductions of 7-8% from 2007-2012 linked to improved prophylaxis, though no similar trends post-2015 in population-level analyses. Immediate post-treatment outcomes frequently involve acute morbidities beyond mortality, including central-line associated in 30-50% of hospitalized cases and requiring extended . Up to 20% of survivors develop intestinal strictures necessitating reoperation within weeks to months, while 10-15% experience recurrent episodes in the acute phase, prolonging NICU stays by 2-4 weeks on average. These outcomes underscore 's role as a leading cause of neonatal gastrointestinal morbidity, accounting for 10-21% of deaths in very low birth weight infants despite advances in neonatal care.

Long-Term Neurodevelopmental and Health Impacts

Survivors of necrotizing enterocolitis (), particularly those with stage II or higher disease requiring , exhibit an elevated risk of neurodevelopmental impairment (NDI) compared to preterm infants without NEC. A of very low-birth-weight infants reported an overall (OR) of 1.82 (95% : 1.46-2.27) for NDI, with surgical NEC conferring a higher risk (OR: 2.00; 95% : 1.43-2.79) than medical NEC alone (OR: 1.08; 95% : 0.76-1.54). Specific deficits include (OR: 1.59; 95% : 1.23-2.07), (OR: 1.65; 95% : 1.27-2.15), and severe (OR: 2.75; 95% : 1.30-5.85), alongside reduced psychomotor developmental index scores in surgical cases (weighted mean difference: -6.56; 95% : -10.82 to -2.30). Up to 45-50% of survivors may experience delays such as cognitive, , or visual impairments by 20-36 months corrected age. These outcomes are potentially mediated by from gut barrier breach, with proinflammatory cytokines (e.g., IL-6, TNF-α) and microbial disrupting the gut-brain axis, leading to injury, microglial activation, and altered production that impair brain development. However, a longitudinal of extremely preterm infants (23-27 weeks ) followed to ages 10 and 15 years found no significant differences in neurodevelopmental scores across medical NEC, surgical NEC, spontaneous intestinal perforation, and control groups after adjustment for confounders like . This suggests that while acute NEC heightens vulnerability—exacerbated by factors such as multiple episodes or lower birth weight—the long-term neurodevelopmental trajectory may align more closely with prematurity-related risks in some populations. Beyond neurodevelopment, NEC survivors face persistent health challenges, including growth faltering in surgical cases (e.g., lower weight z-score of -0.75, height z-score of -0.65, and BMI z-score of -0.55 at 15 years versus controls) and gastrointestinal complications such as strictures, adhesions, , , and , which contribute to rehospitalizations and . Surveys of survivors and parents indicate broad life-impacts, with most reporting enduring effects on physical and , social functioning, and overall , often compounded by psychological distress from abdominal scars or recurrent obstructions. These sequelae underscore the need for multidisciplinary follow-up, though evidence on mitigating interventions remains limited.

History

Early Descriptions and Recognition

The earliest descriptions of what is now recognized as necrotizing enterocolitis (NEC) date to the early , when clusters of fatal intestinal conditions were observed among infants in orphanages. In 1828, physician Charles Marie Denis Billard reported cases in foundling hospitals involving preterm or low-birth-weight infants exhibiting , bloody stools, and rapid deterioration leading to death, often attributed to nosocomial spread in institutional settings. Similarly, in 1850, Austrian pathologist Alois Bednar documented comparable outbreaks in , describing necrotic bowel lesions in neonates housed in specialized care units, further linking the condition to clustered infections among vulnerable infants. These accounts, though lacking modern diagnostic precision, highlighted recurrent patterns of gastrointestinal in preterm neonates, predating widespread neonatal intensive care. Recognition advanced sporadically in the late 19th and early 20th centuries, with pathologists identifying isolated cases of intestinal in infants. In 1888, Richard Paltauf provided one of the first detailed pathological descriptions of transmural in neonatal bowels, associating it with bacterial invasion and , though without establishing a unified . By the mid-20th century, as neonatal care units proliferated, reports increased; in 1952, Schmidt et al. compiled 85 cases of newborns presenting with abdominal symptoms, bloody diarrhea, and autopsy-confirmed bowel , emphasizing radiographic findings like . This period marked growing awareness of the condition's predilection for premature infants fed enterally in hospital environments. The modern term "necrotizing enterocolitis" was coined in 1965 by Mizrahi et al., who described a clinical in premature infants involving feeding intolerance, , bloody stools, and radiographic evidence of intestinal perforation, distinguishing it from prior vague designations like "enteritis necroticans."00145-5/fulltext) Concurrently, in 1964, Berdon et al. provided the first explicit radiographic correlation, identifying and venous gas as hallmarks in affected neonates. These milestones formalized NEC as a distinct , shifting focus from sporadic to a preventable neonatal emergency tied to prematurity and feeding practices.

Evolution of Understanding and Milestones

The recognition of necrotizing enterocolitis () as a distinct clinical entity emerged in the mid-20th century amid rising survival rates for preterm infants in neonatal intensive care units. In 1952, researchers Schmidt and Kaiser reported 85 cases characterized by abdominal symptoms, bloody stools, and pathological findings of intestinal , formally naming the condition "enterocolitis ulcerosa necroticans," which laid the groundwork for its modern . Prior observations, such as identified radiologically in 1951 by Steinen, provided early diagnostic clues linking gaseous cysts in the bowel wall to the disease process. By the 1960s and 1970s, epidemiological patterns revealed epidemics in nurseries, predominantly affecting premature, low-birth-weight infants, with associations to , enteral feeding practices, and microbial overgrowth. Mizrahi et al. in the 1970s implicated like in , shifting focus toward infectious triggers. Concurrently, Barlow and colleagues developed a pup model demonstrating that formula feeding exacerbated intestinal injury compared to , which offered protective mucosal immunity, prompting early prophylactic recommendations for human milk. A pivotal milestone in 1978 was the introduction of the Bell staging system by Bell et al., which classified NEC into stages I (suspected), II (definite), and III (advanced with ) based on clinical, radiographic, and criteria, standardizing , severity assessment, and management protocols across institutions. The 1980s advanced pathophysiological insights with the identification of platelet-activating factor (PAF) as a mediator of ; Gonzalez-Crussi and Hsueh showed in 1983 that PAF induced bowel damage in animal models, while Caplan's later work confirmed its elevation in affected infants, emphasizing inflammatory cascades. Subsequent decades refined multifactorial models integrating gut immaturity, , and immune dysregulation. In 1999, Gewolb et al. highlighted reduced microbial diversity in preterm guts preceding , paving the way for microbiome research. The 2006 discovery by Caplan's group that (TLR4) deficiency prevented in models underscored bacterial-enterocyte signaling defects, influencing targeted therapies. By the 2010s, clinical trials like et al.'s demonstrated that human milk-based fortifiers reduced incidence versus bovine-based ones, reinforcing nutritional prophylaxis amid ongoing debates over pathogenesis endotypes.

Controversies and Debates

Theories of Pathogenesis

The pathogenesis of necrotizing enterocolitis (NEC) remains incompletely understood but is widely regarded as multifactorial, arising from the interplay of intestinal immaturity in preterm neonates, enteral nutrition, microbial , dysregulated innate immunity, and secondary hemodynamic perturbations. No single unifying mechanism has been established, though experimental models emphasize an exaggerated inflammatory response to luminal microbes in the immature gut as a central driver. Prematurity, affecting over 90% of cases, underlies many risks through underdeveloped epithelial barriers, reduced production, and impaired , which collectively heighten vulnerability to injury and bacterial translocation. A prominent theory centers on aberrant (TLR4) signaling in the premature intestine, where upregulated TLR4 expression—normally protective —leads to postnatal to bacterial lipopolysaccharides, triggering mucosal , proinflammatory release (e.g., IL-6, TNF-α), and barrier disruption. models demonstrate that TLR4 activation impairs healing and induces , reducing mesenteric blood flow; genetic or pharmacologic TLR4 inhibition prevents NEC-like in these systems. This immune dysregulation is compounded by immature adaptive responses, including reduced regulatory T cells and heightened neutrophil extracellular trap formation, which amplify tissue damage rather than resolve . Microbial plays a critical initiating role, with preterm infants exhibiting delayed and altered —often dominated by Proteobacteria (e.g., , ) due to cesarean delivery, antibiotics, and NICU environments—preceding onset by days. Unlike term infants, whose foster , this imbalance promotes overgrowth and activation, exacerbating inflammation; (e.g., , ) reduce incidence by 50-80% in meta-analyses, supporting . Enteral feeding, particularly cow's milk-based formula, synergizes with by providing substrates for bacterial proliferation and lacking breast milk's oligosaccharides and , which inhibit TLR4 and enhance barrier integrity; observational data show formula-fed preterms face 2-3 times higher risk. Early theories posited primary from perinatal or as the inciting event, based on 1970s animal models showing mucosal after vascular shunting. However, case-control studies (e.g., from the 1980s onward) found no consistent link to acute hypoxic insults, particularly in stable NICU infants, shifting views to ischemia as a downstream consequence of TLR4-mediated and storms rather than a primary driver. Genetic variants (e.g., in VEGFA or IL-4Rα) may modulate susceptibility by influencing vascular or immune responses, though evidence remains preliminary from genome-wide association studies. Overall, these factors converge in a "cross-talk" model: formula-induced in an immature, TLR4-primed gut elicits unchecked , culminating in and .

Formula Feeding and Associated Litigation

Formula feeding with cow's milk-based products has been associated with an increased risk of necrotizing enterocolitis () in preterm infants compared to feeding with human milk. Meta-analyses of randomized controlled trials indicate that preterm infants fed exclusively human milk experience a of by approximately 38% (RR 0.62, 95% CI 0.42–0.93) relative to those fed formula. Similarly, bovine milk-based formulas have been linked to higher incidence in observational studies of preterm infants, with formula feeding elevating short-term growth but also risk versus human milk. However, consensus statements from agencies including the FDA, CDC, and NIH emphasize that evidence points primarily to the absence of human milk as the key risk factor, rather than specialty preterm formulas directly causing , with the disease's multifactorial involving prematurity, gut immaturity, and microbial . Preclinical data suggest potential mechanisms like formula-induced gut or microbiome alterations, but human clinical evidence for direct causation remains limited, with no definitive proof that formula components are toxic . This association has fueled multidistrict litigation (MDL No. 3026) against manufacturers of cow's milk-based preterm formulas, including () and Benckiser (, via ). As of October 2025, over 760 lawsuits pend in federal court in , alleging that defendants marketed these products for premature infants despite knowing cow's milk increased risk compared to human milk, failed to adequately warn of dangers, and prioritized profits over safer alternatives like donor human milk. Plaintiffs claim resulted from feeding these formulas in neonatal intensive care units (NICUs), leading to intestinal , surgeries, and deaths in affected preterm infants. Defendants counter that stems from underlying prematurity and other clinical factors, not formula per se, and that products carry general warnings while is ideal but often unavailable. Key verdicts include a March 2025 Illinois state court award of $495 million against (reduced from $500 million) for a preterm infant who developed after Similac feeding, and a prior $60 million verdict (including ) against for an case, totaling over $535 million in plaintiff wins. These outcomes hinge on arguments that internal company documents showed awareness of risks from cow's in preemies, yet targeted NICUs without emphasizing human superiority. No global settlements have been reached, with trials ongoing and experts debating whether litigation overstates causation amid epidemiological associations rather than proven .

Recent Advances

Diagnostic Innovations

Abdominal has gained prominence as an adjunct to plain radiography for earlier detection, visualizing dynamic features such as bowel wall thickening exceeding 2.6 mm (pathologic), hyper- or hypoechoic intramural gas (), absent , and portal venous gas often missed on X-rays, which detect in only 50–60% of cases with overall of 55–60%. A 2018 of six studies encompassing 462 infants yielded pooled ultrasound of 22–48% and specificity of 91–99% for key signs including portal venous gas and . Combining ultrasound findings like portal venous gas with radiographic improves to 89% and specificity to 91%. Noninvasive biomarkers facilitate prediction and staging before radiographic changes manifest. Serum or urinary intestinal fatty acid-binding protein (I-FABP), released from damaged enterocytes, demonstrates diagnostic potential with reported sensitivities of 50–83% and specificities of 73–100% across studies from 2013 to 2020. Fecal calprotectin, indicative of intestinal inflammation, elevates markedly in NEC cases, with a 2020 of 13 studies reporting sensitivities of 76–100% and specificities of 39–96%. A 2014 multicenter study identified seven urinary biomarkers differentiating NEC from via AUROC of 0.98. Machine learning and artificial intelligence models integrate multimodal data for enhanced precision. A 2021 single-center random forest algorithm distinguished NEC from focal intestinal perforation with 96% sensitivity and specificity, achieving AUROC 0.98 using clinical and imaging inputs. In a 2025 retrospective study, a multimodal AI framework combining ResNet34 for 408 abdominal X-rays and convolutional networks for 11,016 lab values attained 94% accuracy and AUROC 0.91 in newborns, outperforming clinicians' AUROC of 0.83. These approaches address diagnostic overlaps with conditions like , though validation in prospective trials remains ongoing.

Therapeutic and Preventive Developments

Preventive strategies for necrotizing enterocolitis (NEC) emphasize evidence-based interventions targeting modifiable risk factors in preterm infants. Exclusive human milk feeding, particularly fresh maternal own milk, has been associated with significant reductions in NEC incidence compared to formula-fed cohorts, with meta-analyses indicating up to a 77% when avoiding bovine-based fortifiers or using human milk-derived alternatives. Standardized feeding protocols, including slow advancement of enteral feeds (e.g., 20-30 /kg/day increments) and avoidance of early aggressive trophic feeding, have demonstrated in quality improvement initiatives, reducing NEC rates by 50-60% in very low birth weight infants across multicenter studies. Probiotic supplementation represents a major preventive advance, with multiple-strain formulations (e.g., and species) showing consistent reductions in severe (Bell stage II or higher) incidence. Umbrella meta-analyses of randomized controlled trials report relative risks of 0.54 (95% CI: 0.45-0.65) for and lower all-cause mortality, with as low as 18-34 for preterm infants under 1,500 grams. Single-strain probiotics like BBG-001 have also reduced and in targeted trials, though multi-strain approaches yield broader modulation benefits. These effects stem from enhanced gut barrier integrity and reduced pathogenic overgrowth, though strain-specific efficacy and regulatory concerns over contamination necessitate standardized, high-quality products. Therapeutically, management remains primarily supportive, involving bowel rest, broad-spectrum antibiotics (e.g., ampicillin and gentamicin or metronidazole), and surgical intervention for perforation or necrosis, with peritoneal drainage or laparotomy achieving survival rates of 70-80% in stage III cases. Emerging regenerative approaches, such as mesenchymal stem cell (MSC) administration, have shown promise in preclinical rodent models by attenuating inflammation, promoting intestinal repair, and reducing mortality via immunomodulation and anti-apoptotic effects. Human amniotic fluid-derived stem cells and MSC-derived exosomes similarly mitigate NEC severity in experimental settings, with intraperitoneal delivery enhancing mucosal regeneration. However, as of 2025, these remain investigational, with only early-phase clinical trials registered and no large-scale randomized data establishing efficacy or safety in humans. Targeted therapies inhibiting Toll-like receptor 4 (TLR4) signaling, implicated in NEC pathogenesis, are under exploration but lack approved applications. Ongoing trials prioritize standardized outcome measures to accelerate translation from bench to bedside.

Societal Impact

Advocacy and Awareness Efforts

The NEC Society, established in 2014, serves as the primary advancing advocacy and awareness for necrotizing enterocolitis (NEC), focusing on research funding, policy influence, and education to reduce incidence among premature infants. Through partnerships with clinicians, researchers, and affected families, it promotes evidence-based prevention strategies, such as exclusive human milk feeding, while supporting parent-led initiatives like glossaries and resource sharing to empower families during and . Annual World NEC Awareness Day, observed on May 17, unites global efforts to highlight 's risks and advocate for improved neonatal care protocols. The NEC Society coordinates campaigns on this date, including drives and community events to amplify calls for investment and awareness of modifiable risk factors, such as formula feeding alternatives. Initiatives like the Wave of Light remembrance honor infants lost to NEC and foster dialogue on early intervention. Additional efforts include legislative advocacy, such as pursuing in various U.S. states to designate as a day of recognition and secure commitments to prevention. The Special Interest Group in Necrotizing Enterocolitis (SIGNEC) complements these by facilitating international collaboration among professionals to disseminate and optimize research translation into clinical practice. These combined activities have contributed to increased focus on NEC in neonatal guidelines, though challenges persist in widespread adoption of preventive measures due to resource limitations in under-resourced settings.

Economic and Public Health Burden

Necrotizing enterocolitis (NEC) represents a major public health challenge, predominantly affecting preterm infants, with incidence rates estimated at 5-10% among very low birth weight neonates and up to 9% in extremely premature infants. Mortality rates for NEC range from 20% to 30% overall, escalating to 20-50% in cases requiring surgical intervention, positioning it as one of the leading gastrointestinal causes of neonatal death and a contributor to the top 10 causes of infant mortality in the United States. Survivors often face long-term complications, including short bowel syndrome, neurodevelopmental impairments, and recurrent hospitalizations, amplifying the strain on neonatal intensive care units (NICUs) and pediatric services. The direct economic burden of NEC in the United States is estimated at $500 million to $1 billion annually, driven by prolonged NICU stays, surgical procedures, and requirements. Cases of medical NEC incur average treatment costs exceeding $100,000 per infant, while surgical NEC elevates median total costs to approximately $430,000, surpassing those of other major preterm morbidities like severe or . Post-discharge healthcare expenditures remain elevated for survivors, with medical NEC infants experiencing incremental costs of about $5,000 to $66,000 per year in compared to unaffected peers, attributable to ongoing management of gastrointestinal and developmental sequelae. These figures underscore the potential cost savings from preventive strategies, such as human milk feeding, which studies indicate can reduce NEC incidence and associated expenditures through decreased surgical needs.

References

  1. [1]
    Necrotizing Enterocolitis - StatPearls - NCBI Bookshelf - NIH
    Several risk factors have been identified, but prematurity, low birth weight, and formula feeding have been identified as primary risks[2]. Specifically, high ...
  2. [2]
    Necrotizing Enterocolitis: Practice Essentials, Background, Etiology
    Dec 5, 2024 · Necrotizing enterocolitis affects the gastrointestinal tract and, in severe cases, can cause profound impairment of multiple organ systems.Practice Essentials · Background · Etiology · Epidemiology<|separator|>
  3. [3]
    Infant Mortality in the United States Due to Necrotizing Enterocolitis ...
    Mar 3, 2023 · The NEC-IMR peaked in 2005 at 13.2 (95% CI, 12.1-14.3) per 100 000 live births and was lowest in 2020 at 8.3 (95% CI, 7.4-9.3) per 100 000 live ...
  4. [4]
    Necrotizing enterocolitis: new insights into pathogenesis and ...
    This Review outlines current approaches for the treatment and diagnosis of necrotizing enterocolitis and examines the progress made in our understanding of the ...
  5. [5]
    Incidence, Treatment, and Outcome Trends of Necrotizing ... - Frontiers
    May 12, 2020 · Mortality rate may reach up to 20–45%, which makes NEC one of the leading causes of death in preterm infants (5, 6). The present study aims to ...
  6. [6]
    Necrotizing Enterocolitis in Full-Term Infants: Case–Control Study ...
    The incidence of NEC in full-term infants increased from 0.16 to 0.71 per 1000 live births in the 5-year period. Mean birth weight was 2829 g. All the NEC ...
  7. [7]
    Racial/ethnic differences in necrotizing enterocolitis incidence and ...
    Aug 7, 2018 · Among infants with NEC, there was a trend toward higher rates of surgical NEC among Black infants (36%) compared to Hispanic (33%) and White (34 ...
  8. [8]
    Racial Disparities in Necrotizing Enterocolitis - Frontiers
    Feb 17, 2021 · Necrotizing enterocolitis (NEC) is a serious disease of the intestinal tract affecting 5-10% of preterm infants with up to 50% mortality in ...
  9. [9]
    Global incidence of Necrotizing Enterocolitis: a systematic review ...
    Jul 13, 2020 · Multiple population-based studies, some based on large cohort studies, have reported the incidence of NEC to vary from 2 to 13% in preterm and Very Low Birth ...
  10. [10]
    Global incidence of Necrotizing Enterocolitis: a systematic ... - PubMed
    Jul 13, 2020 · Seven out of 100 of all VLBW infants in NICU are likely to develop NEC. However, there were considerable heterogeneity between studies.
  11. [11]
    Epidemiology and Trends of Necrotizing Enterocolitis in Sweden
    Aug 1, 2013 · NEC incidence is known to vary geographically with frequencies thought to be especially low in Japan, Switzerland, and some Scandinavian ...
  12. [12]
    Global incidence of Necrotizing Enterocolitis: a systematic review ...
    The incidence of NEC was 7.8% as 199 cases developed necrotizing enterocolitis among 2549 preterm babies born before 29 weeks of gestation. Narang et al. 1993, ...
  13. [13]
    Trends and Racial and Geographic Differences in Infant Mortality in ...
    Mar 3, 2023 · The NEC-IMR peaked in 2005 at 13.2 (95% CI, 12.1-14.3) per 100 000 live births and was lowest in 2020 at 8.3 (95% CI, 7.4-9.3) per 100 000 live ...
  14. [14]
    Necrotizing enterocolitis: current understanding of the prevention ...
    Jan 10, 2024 · Recent reports have noted a declining incidence of NEC in the United States, from 7.1% in 2005 to 5.2% in 2014, using this definition [24].
  15. [15]
    Factors associated with the increased incidence of necrotising ...
    A recent Swedish national cohort study of extremely preterm infants showed an increased NEC incidence over 10 years. During the same period, mortality and the ...Methods · Results · Discussion
  16. [16]
    Trends and risk factors analysis of NEC in preterm infants over 9 years
    May 15, 2024 · Data of 2020 showed that the global incidence of NEC in very low birth weight (VLBW) infants was about 7% [1], but the incidence of NEC was ...
  17. [17]
    Temporal and seasonal variations in incidence of stage II and III ...
    Temporal and seasonal factors may play a role in NEC with a peak incidence in infants born in April/May and periodicity spikes approximately every 10 years.<|separator|>
  18. [18]
    Pathogenesis of Necrotizing Enterocolitis: Modeling the Innate ...
    This review provides an updated summary of the components of the innate immune system involved in NEC pathogenesis.
  19. [19]
    New insights into the pathogenesis of necrotizing enterocolitis and ...
    This activation results in apoptosis and necroptosis of the intestinal epithelium, resulting in bacterial translocation and TLR4 activation on the mesentery, ...
  20. [20]
    Role of the microbiome in pathophysiology of necrotising ...
    Nov 2, 2023 · Dysbiosis anticipating necrotizing enterocolitis in very premature infants. ... A critical role for Tlr4 in the pathogenesis of necrotizing ...
  21. [21]
    Necrotizing Enterocolitis and the Microbiome: Current Status and ...
    However, multiple lines of evidence suggest that the gut microbiome plays a major role in NEC development. First, NEC does not occur in utero, an interval ...
  22. [22]
    Gut microbiome and necrotizing enterocolitis: Understanding the ...
    May 11, 2022 · We discuss the contribution of the gut microbiome and potential therapeutics, notably lactadherin, that may promote gut homeostasis to alleviate NEC.
  23. [23]
    The incidence and modifiable risk factors for necrotizing enterocolitis ...
    Necrotizing Enterocolitis (NEC) is a gastrointestinal emergency, most cases (90%) are reported in infants who are born before 37 weeks' gestation [1].<|separator|>
  24. [24]
    Incidence and enteral feed antecedents of severe neonatal ...
    Nov 7, 2016 · Overall, 531 (0·4%) babies developed severe necrotising enterocolitis, of whom 247 (46·5%) died (139 after laparotomy). 462 (3·2%) of 14 678 ...
  25. [25]
    Evaluation of Incidence and Characteristics of Necrotizing ...
    The incidence of NEC was found as 7.5% among the total patient population. Mean gestational age and birth weight of NEC patients were 27.5±2.5 weeks and 1044± ...
  26. [26]
    Understanding the Susceptibility of the Premature Infant to ... - Nature
    Immaturity of the intestinal epithelial barrier and neonatal mucosal immune system predispose the premature infant to bacterial infection/invasion triggering ...
  27. [27]
    Hypothesis: inappropriate colonization of the premature intestine ...
    Jun 1, 2001 · ... immature gastrointestinal immune defense system places a preterm infant at higher risk for NEC. The premature infant has lower gastric acid ...<|control11|><|separator|>
  28. [28]
    Necrotizing enterocolitis: Bench to bedside approaches ... - Frontiers
    Here we review predisposing factors, status of unwarranted immune responses, and microbial pathogenesis in NEC based on currently available scientific evidence.
  29. [29]
    Current Knowledge of Necrotizing Enterocolitis in Preterm Infants ...
    Underdeveloped cardiac, respiratory, gastrointestinal, and immune systems in the preterm period increase the risk of necrotizing enterocolitis (NEC), a serious ...
  30. [30]
    Necrotizing Enterocolitis | Children's Hospital Los Angeles
    Necrotizing enterocolitis (NEC) is a devastating disease that affects mostly the intestine of premature infants.Etiology And Risk Factors · Clinical Presentation · Treatment
  31. [31]
    Risk factors for necrotizing enterocolitis in neonates - NIH
    Apr 14, 2017 · Significant prognostic factors for NEC reported in at least two studies were: low birth weight, small for gestational age, low gestational age, assisted ...
  32. [32]
    Current Knowledge of Necrotizing Enterocolitis in Preterm Infants ...
    Jan 11, 2017 · Several studies have indicated that bovine milk–based infant formulas lead to a higher incidence of NEC in preterm infants than does human milk (HM).
  33. [33]
    The Impact of Human Milk on Necrotizing Enterocolitis - NIH
    May 6, 2020 · RCTs meta-analysis indicates a risk reduction of NEC using human milk respect to formula: Relative risk (RR) = 0.62 (0.42–0.93).Missing: protection | Show results with:protection
  34. [34]
    Necrotizing Enterocolitis Treatment & Management
    Dec 5, 2024 · McKeown et al reported that rapid increase in feeding volume (>20 mL/kg/d) was associated with higher risk of NEC. Later, however ...<|separator|>
  35. [35]
    Controlled Trial of Two Incremental Milk-Feeding Rates in Preterm ...
    Oct 4, 2019 · Observational studies have shown a higher risk of necrotizing enterocolitis with rapid advancement of feeding volumes but are subject to ...
  36. [36]
    Enteral Feeding Regimens and Necrotising Enterocolitis in Preterm ...
    These data suggest that the duration of trophic feeding and rate of advancement of feed volumes may be modifiable risk factors for NEC in preterm infants.
  37. [37]
    Short versus Extended Duration of Trophic Feeding to Reduce Time ...
    Jul 14, 2017 · A short duration of trophic feeding is not associated with a higher risk of NEC, but our study was underpowered for this safety outcome. ...
  38. [38]
    Impact of neonatal nutrition on necrotizing enterocolitis - PMC
    Similarly, formula feeding in preterm infants born less than 1500 grams is associated with an increased risk of NEC development compared to donor milk feeds.
  39. [39]
    Maternal and placental risk factors associated with the development ...
    Apr 30, 2019 · Results: We identified 136 cases and 134 controls. The group of mothers of NEC-neonates had a higher prevalence of preeclampsia, CC, and AAUF.<|separator|>
  40. [40]
    Maternal Risk Factors for Neonatal Necrotizing Enterocolitis - PMC
    Low birth weight and fetal growth restriction are also known risk factors for NEC. It is plausible that chronic intrauterine hypoxia, such as what is seen in ...
  41. [41]
    [PDF] Risk Factors of Necrotizing Enterocolitis in Preterm Infants
    A recently published meta-analysis revealed maternal gestational diabetes mellitus, intrahepatic cholestasis in pregnancy, preeclampsia, neonatal asphyxia, ...
  42. [42]
    Maternal, fetal and perinatal factors associated with necrotizing ...
    We found independent positive associations with necrotizing enterocolitis for isoimmunization, fetal distress, cesarean section, neonatal bacterial infection.<|separator|>
  43. [43]
    Factors influencing necrotizing enterocolitis in premature infants in ...
    Feb 29, 2024 · In summary, our study suggests that septicemia, blood transfusion, neonatal asphyxia, pneumonia, infection, congenital heart disease, ICP, GDM, ...
  44. [44]
    Risk factors of necrotizing enterocolitis in twin preterm infants
    Mar 23, 2024 · Perinatal risk factors: premature rupture of membranes, placenta abnormalities, and birth asphyxia; 3. Feeding status: microfeeding, feeding ...
  45. [45]
    Current Understanding of Transfusion-associated Necrotizing ... - NIH
    They concluded that RBC transfusions significantly reduced the risk of NEC in ≤1,000 g infants, but noted a trend towards increased risk of NEC in infants with ...
  46. [46]
    RBC transfusion and necrotizing enterocolitis in very preterm infants
    Jun 21, 2024 · The causal relationship between Packed red blood cell (RBC) transfusion and necrotizing enterocolitis (NEC) remains uncertain.Missing: iatrogenic | Show results with:iatrogenic
  47. [47]
    Early antibiotics and risk for necrotizing enterocolitis in premature ...
    Feb 13, 2023 · Several retrospective studies have demonstrated that early antibiotic use is associated with an increased risk for developing NEC.Missing: iatrogenic | Show results with:iatrogenic
  48. [48]
    Risk factors and outcomes of infants with necrotizing enterocolitis - NIH
    Sep 10, 2025 · The overall incidence rate of NEC in this study was 3.8 per 1,000 live births and 4.5% amongst VLBW infants. Formula feeding, blood transfusion, ...
  49. [49]
    Necrotizing Enterocolitis Clinical Presentation - Medscape Reference
    Dec 5, 2024 · The clinical presentation of necrotizing enterocolitis (NEC) includes nonspecific aspects of the history, such as vomiting, diarrhea, feeding intolerance and ...
  50. [50]
    What are the symptoms of necrotizing enterocolitis (NEC)? | NICHD
    Dec 16, 2021 · Common symptoms include not being able to digest food; bloating, swelling, and discoloration of the stomach; diarrhea; and more.
  51. [51]
    Defining Necrotizing Enterocolitis: Current Difficulties and Future ...
    Bell staging system included a set of characteristics used to classify infants into 1 of 3 stages of NEC (Figures 1 and 2), which were used to stratify ...
  52. [52]
    [PDF] Evaluation and Management of Suspected, Medical and Surgical ...
    Dec 8, 2022 · Necrotizing enterocolitis (NEC) is an inflammatory disease of the gastrointestinal tract characterized by ischemic necrosis of the intestinal ...
  53. [53]
    Bell's staging of necrotizing enterocolitis | Radiology Reference Article
    Aug 31, 2025 · Bell's staging is in common use (c. 2024), although there are many other systems for classifying necrotizing enterocolitis 3. Classification.
  54. [54]
    Necrotizing Enterocolitis Imaging - Medscape Reference
    Mar 4, 2020 · The Bell system is the staging system most commonly used to describe necrotizing enterocolitis (NEC). ... Bell stage I is suspected disease. Stage ...
  55. [55]
    Necrotizing Enterocolitis (NEC): What is it, Causes & Treatment
    NEC is a serious gastrointestinal problem that mostly affects premature babies. The condition inflames intestinal tissue, causing it to die.
  56. [56]
    Necrotizing Enterocolitis in Preterm Infants
    Jul 22, 2021 · Stage III disease is typically advanced disease, where the infant is more severely ill and exhibiting hemodynamic instability. Stage IIIB NEC is ...
  57. [57]
    Staging of necrotising enterocolitis by Bell's criteria is supported by a ...
    Conclusion: An analysis of the pattern of clinical and radiographic findings in a 2006-2015 population of NEC cases supported Bell's 1978 staging system.
  58. [58]
    Necrotizing Enterocolitis - PMC - PubMed Central
    Sustained overproduction of NO secondary to up-regulation of NOS-2 in the GI tract in response to an inflammatory stimulus has been suggested to induce cellular ...
  59. [59]
    Necrotizing Enterocolitis (NEC)
    Stage 1, suspected NEC, includes symptoms such as bloody stools, diminished activity (lethargy), slow heart rate, an unstable temperature, mild abdominal ...
  60. [60]
    Standardizing the Evaluation and Management of Necrotizing ...
    Sep 27, 2022 · Using this proposed, unit-developed guideline, we aimed to align our current management of NEC, thereby decreasing variation of practice within ...
  61. [61]
    Neonatal Necrotizing Enterocolitis - PMC - NIH
    1.Abdominal distension, blood in stool, and pneumatosis intestinalis on x-ray are considered the classical features of NNEC.
  62. [62]
  63. [63]
    Ultrasound for the Early Detection and Diagnosis of Necrotizing ...
    Jul 23, 2025 · Conclusions: Bowel ultrasound is a valuable adjunct to conventional imaging in NEC diagnosis. Standardized protocols, validation of advanced ...
  64. [64]
    Photoacoustic imaging for non-invasive assessment of biomarkers ...
    Jun 24, 2024 · This preclinical study presents PAI as an emerging diagnostic imaging modality for intestinal disease assessment in premature infants.
  65. [65]
    Current status of laboratory and imaging diagnosis of neonatal ... - NIH
    Jul 25, 2018 · This review summarizes what is known on the laboratory and instrumental diagnostic strategies needed to improve neonatal outcomes.
  66. [66]
    Biomarkers of Necrotizing enterocolitis in the Era of Machine ... - NIH
    Despite decades of research in NEC, no reliable biomarkers can accurately diagnose NEC or predict patient prognosis. The recent emergence of multi-omics could ...
  67. [67]
    The value of intestinal fatty acid binding protein as a biomarker ... - NIH
    Apr 30, 2025 · Among these, intestinal fatty acid binding protein (I-FABP) has emerged as the most promising candidate biomarker. I-FABP is a lipid-binding ...
  68. [68]
    Biomarkers for Infants at Risk for Necrotizing Enterocolitis - Nature
    I-FABP was found to be associated with advanced stages of NEC, whereas liver fatty acid binding protein was found to be significantly elevated in infants with ...
  69. [69]
    Biomarkers of Necrotizing Enterocolitis: The Search Continues
    Jan 21, 2022 · CRP (C-reactive Protein); PCT (Procalcitonin); IMA (Ischemia-modified ... Urine protein biomarkers for the diagnosis and prognosis of necrotizing ...
  70. [70]
    Biomarkers of gut injury in neonates – where are we in predicting ...
    Nov 28, 2022 · Summary of the main studies reporting on gut tissue biomarkers (FABPs, calprotectin, VOC and TFF) as predictors of necrotising enterocolitis ( ...
  71. [71]
    Serum HMGB1 level is correlated with serum I-FABP level in ...
    Aug 21, 2021 · In the present study, it was observed I-FABP and inflammatory factors CRP, IL-1β, IL-6 and TNF-α were all elevated in NEC patients. Furthermore, ...
  72. [72]
    Protective effects of different doses of human milk on neonatal ...
    Sep 11, 2020 · We aim to summarize the evidence focusing on the effects of various doses of human milk on the risk of neonatal necrotizing enterocolitis ...Missing: protection | Show results with:protection
  73. [73]
    NEC-zero recommendations from scoping review of evidence to ...
    Dec 18, 2017 · Meta-analysis of data from infants weighing <1250 g fed donor human milk based fortifier had reduced odds of NEC compared to those fed cow's ...
  74. [74]
    Probiotics for prevention of necrotising enterocolitis in very preterm ...
    Probiotics may reduce the risk of NEC (RR 0.54, 95% CI 0.46 to 0.65; I² = 17%; ... Published. 26 July 2023. Full review on the Cochrane Library · Cochrane.
  75. [75]
    Probiotics to prevent necrotising enterocolitis in very preterm or very ...
    Oct 15, 2020 · Combined analyses showed that giving very preterm and very low birth weight infants probiotics may reduce the risk of necrotising enterocolitis.
  76. [76]
    Probiotics in the Prevention and Treatment of Necrotizing Enterocolitis
    May 4, 2021 · Network meta-analysis suggests the preventive efficacy of Bifidobacterium and Lactobacillus spp., but even more for mixtures of Bifidobacterium, Streptococcus, ...
  77. [77]
    Prenatal and postnatal corticosteroid therapy to prevent ... - PubMed
    These data support the hypothesis that the incidence of NEC is significantly reduced after prenatal steroid treatment.
  78. [78]
    Antenatal Corticosteroid Administration for Reducing the Risk of ...
    The use of antenatal corticosteroids is the only effective intervention for reducing neonatal complications such as RDS, intracranial hemorrhage, necrotizing ...
  79. [79]
    Necrotizing enterocolitis intestinal barrier function protection by ...
    Jan 19, 2021 · Our data show that a single dose of antenatal corticosteroids can significantly decrease experimental NEC in a neonatal rat model. Antenatal ...
  80. [80]
    Prevention of necrotizing enterocolitis in premature infants - NIH
    Based on their meta-analysis, the authors conclude that the current evidence does not support the use of prophylactic antibiotics to reduce the incidence of ...
  81. [81]
    Prevention Strategies and Management of Necrotizing Enterocolitis
    Jun 3, 2024 · The most important strategy to prevent NEC is to provide preterm infants with a human milk diet, minimize exposure to antibiotics and avoid medications that ...<|separator|>
  82. [82]
    Neonatal necrotizing enterocolitis: Prevention - UpToDate
    Avoid prolonged antibiotic use · Avoid gastric acid suppression · Prevent severe anemia/Decrease exposure to RBC transfusion · Close monitoring during and after ...
  83. [83]
    Formula versus donor breast milk for feeding preterm or low birth ...
    Jul 19, 2019 · Necrotising enterocolitis. Meta‐analysis of data available from nine trials showed a higher risk of necrotising enterocolitis in the formula ...
  84. [84]
    A Systematic Review and Meta-Analysis of Human Milk Feeding and ...
    It aims to provide a direct comparison between exclusive human milk (EHM) and exclusive preterm formula (EPTF), to examine whether any HM was protective when ...
  85. [85]
    The fifty billion dollar question: does formula cause necrotizing ...
    Mar 26, 2025 · ... formula feeding on ... Surgical necrotizing enterocolitis risk factors in extremely preterm infants: a Korean nationwide cohort study.
  86. [86]
    [PDF] Nutritional Management of the Infant with Necrotizing Enterocolitis
    Minimal enteral nutrition or trophic feedings in the first few weeks of life have been shown to decrease the incidence of NEC in VLBW infants. Berseth, et al ...
  87. [87]
    Early enteral feeding in preterm infants - ScienceDirect.com
    Trials targeting such high-risk preterm infants have demonstrated that progressive enteral feeding started in the first 4 days is safe and does not lead to ...
  88. [88]
    Slow advancement of enteral feed volumes to prevent necrotising ...
    Current evidence suggests that the slow advancement of enteral feed volumes does not reduce the risk of necrotising enterocolitis or death in very low birth ...
  89. [89]
    Optimizing Nutritional Strategies to Prevent Necrotizing Enterocolitis ...
    The implementation of standardized feeding protocols to manage trophic feeds, residuals, and timing of advancement of feeds may help in lowering NEC rates [70].
  90. [90]
    Effects of synbiotics on necrotizing enterocolitis and full enteral ...
    Sep 13, 2024 · In the present study, synbiotics decreased the risk of NEC of all stages by 78% in VLBW neonates compared to placebo. Moreover, the risk ...1. Introduction · 2. Methods · 3. Results<|control11|><|separator|>
  91. [91]
    Comparative efficacy of different single drugs to prevent necrotizing ...
    Sep 9, 2024 · Arginine demonstrated the highest clinical efficacy in reducing the incidence of NEC, with probiotics being the next most effective and the placebo being the ...
  92. [92]
    Necrotizing Enterocolitis - Pediatrics - Merck Manuals
    Supportive treatment using fluid resuscitation, nasogastric suction, broad-spectrum antibiotics, and parenteral nutrition is effective in 50 to 75% of cases.
  93. [93]
    Necrotizing Enterocolitis: Antibiotic Selection & Duration of Therapy
    Follow algorithm below for management of necrotizing enterocolitis in the Intensive Care Nursery. Click here for a PDF copy of the ICN algorithm.
  94. [94]
  95. [95]
    Necrotizing Enterocolitis | Pediatrics In Review - AAP Publications
    Dec 1, 2017 · Necrotizing enterocolitis (NEC) is a frequently encountered condition in the premature neonate, which can have devastating effects.
  96. [96]
    Surgical necrotizing enterocolitis - PMC - NIH
    They also found 27% of infants with NEC required surgical intervention with an overall case-fatality rate of 15%. A review from the National Institute of Child ...
  97. [97]
    Methods of identifying surgical Necrotizing Enterocolitis—a ... - Nature
    Jun 7, 2024 · Bowel ultrasound for predicting surgical management of necrotizing enterocolitis: a systematic review and meta-analysis. Pediatr. Radio. 48 ...
  98. [98]
    Survey on surgical treatment of neonatal necrotizing enterocolitis in ...
    Aug 8, 2023 · At laparotomy, surgical treatments vary according to NEC severity. Infants are fasted for 5–7 days by 55.2% of surgeons postoperatively. Most ...
  99. [99]
    Laparotomy versus Peritoneal Drainage for Necrotizing Enterocolitis ...
    May 25, 2006 · We found no significant reduction in the risk of mortality after primary peritoneal drainage as compared with laparotomy (relative risk, 1.03; ...
  100. [100]
    Laparotomy versus Peritoneal Drainage as Primary Treatment for ...
    Jul 6, 2023 · Compared to LAP, PD as primary surgical treatment for sNEC or SIP has similar survival rates when analyzing data from RCTs.
  101. [101]
    Peritoneal Drainage versus Laparotomy for Necrotizing Enterocolitis ...
    Jun 1, 2010 · PD is associated with 55% excess mortality compared with LAP. Pediatric surgeons must individually assess and select patients with NEC and IP ...
  102. [102]
    Does the Timing of Surgical Intervention Impact Outcomes in ...
    May 24, 2024 · Conclusion: Infants with NEC who underwent early surgical intervention had a higher mortality and more bowel resected. While this study has a ...
  103. [103]
    Association of timing of surgery and outcomes in preterm infants with ...
    Preterm infants with 48 hours or less to surgery from NEC trended towards lower odds of death than subjects with more than 48 hours to surgery from NEC.
  104. [104]
    Risk factors and outcomes of infants with necrotizing enterocolitis
    Sep 9, 2025 · Formula feeding, blood transfusion, and a longer duration of antibiotic exposure were identified as risk factors. The rate of culture-proven ...
  105. [105]
    Necrotizing Enterocolitis: What's New and What's Next? - PMC
    The mortality rate for NEC is as high as 50%, which makes it major cause of death in preterm infants [4,7]. Nearly 70% of cases occur in preterm infants born ...
  106. [106]
    Contemporary Outcomes for Infants with Necrotizing Enterocolitis ...
    Jan 22, 2020 · Overall mortality was 23.5% in all neonates with confirmed NEC (Bell stage 2a+) (95% CI 18.5%-28.8%), 34.5% (30.1%-39.2%) for neonates that ...
  107. [107]
    In-hospital mortality among neonates with necrotising enterocolitis in ...
    NEC is a devastating disease with a mortality rate of 10%–50%. However, mortality might approach 100% among neonates with advanced stages of NEC.1 In Ethiopia, ...<|separator|>
  108. [108]
    Analysis of Factors Influencing Outcomes in Preterm Infants With ...
    May 12, 2022 · Approximately 40% of neonates with NEC require surgery, which are at a high risk of death or require long-term hospitalization (3). With the ...
  109. [109]
    Surgical necrotizing enterocolitis risk factors in extremely preterm ...
    Aug 24, 2024 · The incidence of necrotizing enterocolitis (NEC) is significantly associated with gestational age (GA). This study aimed to investigate risk ...
  110. [110]
    A predictive model for prognosis in infants with surgical necrotizing ...
    Aug 2, 2025 · Surgical intervention could improve the prognosis of infants with necrotizing enterocolitis (NEC), but it's also an independent risk factor ...
  111. [111]
    Research Reveals Fewer Infants are Dying from NEC
    Apr 28, 2023 · The study revealed that while NEC-related deaths increased early in the 21st century, NEC-related deaths declined by 7.7% each year from 2007 through 2012.Missing: neonates | Show results with:neonates
  112. [112]
    Changes in the Incidence and Severity of NEC over the Last Decade
    May 19, 2025 · Trends in incidence and outcomes of necrotizing enterocolitis over the last 12 years: A multicenter cohort analysis. J. Pediatr. Surg. 2020 ...
  113. [113]
    Mortality of necrotizing enterocolitis does not vary across tertiary ...
    Overall mortality rate was 23.3%. Median overall and surgical NEC patient volume per hospital were 53 [IQR 41-65] and 11 [IQR 7-16], respectively. A chi ...
  114. [114]
    Neurodevelopmental Outcomes of Very Low-Birth-Weight Infants ...
    Survivors of stage II or higher NEC are at risk for long-term neurodevelopmental impairment, especially if they require surgery for the illness.
  115. [115]
    Role of gut-brain axis in neurodevelopmental impairment ... - Frontiers
    NEC survivors often have life-long consequences, including neurodevelopmental delay, failure to thrive, gastrointestinal strictures and adhesions, cholestasis, ...Abstract · Introduction · Neurodevelopmental... · Proposed mechanisms...
  116. [116]
    Long-Term Outcome of Necrotizing Enterocolitis and Spontaneous ...
    Oct 6, 2022 · Both NEC and SIP have been associated with increased risk of neurodevelopmental (ND) impairment (NDI). Severe NDI affects 25% to 59% of ...
  117. [117]
    Long-term outcomes and life-impacts of necrotizing enterocolitis
    NEC survivors and parents of children affected by NEC experience long-term complications that impact their physical and mental health, social experiences, and ...
  118. [118]
    Necrotizing enterocolitis: 150 years of fruitless search for the cause
    It was observed in the foundling hospitals of Paris (Billard 1828) and Vienna (Bednar 1850) and, as it occurred in clusters, was regarded as a nosocomial ...
  119. [119]
    Necrotizing enterocolitis--150 years of fruitless search for the cause
    Necrotizing enterocolitis (NEC) is not a new disease but one that has been reported since special care units began to house preterm infants.
  120. [120]
    What Really Causes Necrotising Enterocolitis? - PMC - NIH
    The condition was first described by Paltauf in 1888 but the term “necrotising enterocolitis ... conducted a study in 2010 of 14 confirmed cases of NEC and ...
  121. [121]
    Necrotizing Enterocolitis: Pathophysiology from a historical context
    In this review, we will describe NEC from a historical context and summarize seminal findings that underscore the importance of enteral feeding.Enteral Feedings In Nec... · Effect Of Microbiome · Bacterial-Enterocyte...<|control11|><|separator|>
  122. [122]
    Necrotizing Enterocolitis-150 Years of Fruitless Search for the Cause
    Aug 7, 2025 · In 1965, Mizrahi and colleagues first used the term "necrotizing enterocolitis" to describe this syndrome that consisted of abdominal distension ...<|separator|>
  123. [123]
    Advances in our understanding of the molecular pathogenesis of ...
    Apr 25, 2022 · This article will focus on the current understanding of the molecular pathogenesis of NEC with a focus on the inflammatory, immune, infectious, and genetic ...
  124. [124]
    NECROTIZING ENTEROCOLITIS: The Search for a Unifying ...
    HYPOXIA-ISCHEMIA​​ Early theories of the pathogenesis of NEC suggested circulatory perturbations to be the most important determinants of pathogenesis. 74, 113 ...
  125. [125]
    Evidence based feeding strategies before and after the development ...
    Necrotizing enterocolitis (NEC) is a devastating disease of premature infants and feeding practices have been suggested to be a modifiable risk factor. Breast ...
  126. [126]
    FDA, CDC, NIH: Evidence points to lack of human milk, not specialty ...
    Oct 9, 2024 · There is no conclusive evidence that specialty formulas for preterm infants cause necrotizing enterocolitis (NEC), according to a consensus ...Missing: studies | Show results with:studies
  127. [127]
  128. [128]
    Baby Formula NEC Lawsuit & Settlement October 2025 Update
    As of October 2025, there were 761 necrotizing enterocolitis baby formula lawsuits pending in multidistrict litigation. MDL 3026 is before U.S. District ...Lawsuit Updates · Expert Perspectives on NEC... · Why Did People Sue? · Brands
  129. [129]
    NEC Baby Formula Lawsuit & Settlement | October 2025 Update
    Oct 2, 2025 · NEC baby formula litigation update and settlement amount talk after two big jury verdict in state court totaling $535 million.
  130. [130]
    Ongoing Litigation Regarding the Use of Cow's Milk Formulas and ...
    Abbott defense attorneys argued that the infant in their specific lawsuit who developed NEC had medical issues during pregnancy and delivery resulting in their ...<|separator|>
  131. [131]
    NEC Cow's Milk Baby Formula Lawsuit | Birth Injury Center
    Sep 6, 2023 · The lawsuits allege that the cow's milk in the formulas caused the infants to develop NEC and that Abbott and Mead Johnson failed to place ...
  132. [132]
    Imaging for Diagnosis and Assessment of Necrotizing Enterocolitis
    Abdominal ultrasound (AUS) has emerged as a readily available, noninvasive imaging tool that may be a valuable adjunct to plain radiographs for evaluating NEC.
  133. [133]
    Recent advances in our understanding of NEC diagnosis, prognosis ...
    Jul 31, 2023 · Many recent studies have reported novel methods of diagnosis of NEC with the aim of earlier and more accurate identification. These include imaging and machine ...
  134. [134]
    Emerging Biomarkers for Prediction and Early Diagnosis of ...
    Dec 8, 2020 · Among the biomarkers evaluated for prediction and diagnosis of NEC, fecal calprotectin (CP), intestine-fatty acid binding protein (I-FABP), ...
  135. [135]
    Advances in Artificial Intelligence and Machine Learning for ... - MDPI
    Development of an artificial intelligence-based multimodal model for assisting in the diagnosis of necrotizing enterocolitis in newborns: A retrospective study.
  136. [136]
    [PDF] Prevention of necrotising enterocolitis (NEC)
    A limited number of strategies have proven effective in reducing the prevalence of the most severe stages of NEC (5), including human milk, with fresh maternal ...
  137. [137]
    Quality improvement interventions to prevent neonatal necrotizing ...
    May 23, 2025 · Quality improvement may reduce the incidence and severity of NEC in preterm infants. We evaluated quality improvement interventions (QIIs) that ...
  138. [138]
    Quality Improvement Project to Improve Adherence to Best Practices ...
    The implementation of several evidence-based interventions through this QI initiative reduced the NEC rate among VLBW infants by 60% over two years. The ...
  139. [139]
    The effectiveness of treatment with probiotics in preventing ...
    Apr 11, 2025 · Probiotic supplementation has been proposed as a preventive measure for necrotizing enterocolitis (NEC) in preterm infants.
  140. [140]
    Probiotics, Prebiotics, Lactoferrin, and Combination Products for ...
    Oct 2, 2023 · The most severe harm associated with the use of probiotics for prevention of morbidity and mortality in preterm infants is sepsis caused by ...
  141. [141]
    Full article: Efficacy of probiotic supplementation in preventing ...
    Probiotic supplementation with BBG001 appears effective in reducing NEC incidence, bloodstream infections, and infection-related deaths in preterm infants.
  142. [142]
    Current and future methods of probiotic therapy for necrotizing ...
    Through meta-analysis of well-designed RCTs studying the utility of probiotics in preventing NEC in VLBW preterm infants, it is clear that probiotics remain an ...
  143. [143]
    Effect of probiotics on necrotizing enterocolitis in preterm infants
    Mar 27, 2025 · Our study revealed that most probiotics can effectively reduce the incidence of NEC (at or beyond Bell's stage II).
  144. [144]
    Translating regenerative medicine therapies in neonatal necrotizing ...
    May 28, 2024 · ... clinical evaluation. With the participants ... New Medical and Surgical Insights Into Neonatal Necrotizing Enterocolitis: A Review.
  145. [145]
    Stem cell therapy as a promising strategy in necrotizing enterocolitis
    Sep 6, 2022 · Animal studies on stem cell therapy have made great progress, and the anti-inflammatory, anti-apoptotic, and intestinal barrier enhancing ...
  146. [146]
    Cell-based therapies in preclinical models of necrotizing enterocolitis
    Feb 26, 2025 · To date, one clinical trial has been registered using cell therapy ... Mesenchymal stem cell therapy in necrotizing enterocolitis: a rat study.
  147. [147]
    Stem cells and exosomes: promising candidates for necrotizing ...
    Jun 5, 2021 · To date, there is no registered clinical trial of stem cells or exosomes for NEC. Our integration of current findings on fundamental and ...
  148. [148]
    Outcome Reporting in Interventional Necrotizing Enterocolitis Studies
    Despite an increasing necrotizing enterocolitis (NEC) incidence, treatment strategies have failed to make major advancements towards improved NEC outcomes.Review Article · 3. Results · 3.1. Reported Outcomes
  149. [149]
  150. [150]
    NEC Society recognizes a decade of impact - EurekAlert!
    Aug 29, 2024 · Since 2014, the NEC Society has worked tirelessly to protect infants from the devastation of necrotizing enterocolitis, a severe and poorly ...Missing: groups | Show results with:groups
  151. [151]
  152. [152]
    Advocacy in Action: Finding My Voice with the NEC Society | News
    Sep 26, 2025 · Families facing NEC deserve to understand what's happening to their children, and making this glossary gave me a tangible way to support them. I ...
  153. [153]
    World NEC Awareness Day: Uniting to Combat Necrotizing ...
    May 17, 2024 · A day dedicated to raising awareness about Necrotizing Enterocolitis (NEC), a devastating condition affecting premature infants worldwide.
  154. [154]
    NEC awareness day, 17 May 2025. What is new in NEC prevention?
    May 17, 2025 · NEC awareness day, 17 May 2025. What is new in NEC prevention? · Probiotics. · Prebiotics · Breast Milk · Oro-pharyngeal Colostrum · Reducing ...Missing: campaigns initiatives
  155. [155]
    NEC Society on Instagram: " We love seeing our global community ...
    May 16, 2025 · May 17 is NEC Awareness Day and we need YOU to join us as we raise our voices for the urgent need to advance NEC research, education, and advocacy!Missing: campaigns initiatives<|control11|><|separator|>
  156. [156]
    Honoring Little Loves: NEC Society's Wave of Light Campaign
    #NECchicago created a transformative space for learning, ...Missing: campaigns initiatives
  157. [157]
    Special Interest Group in Necrotizing Enterocolitis
    The aim of the Special Interest Group in Necrotizing Enterocolitis is to facilitate knowledge sharing, networking and collaboration to optimise research.
  158. [158]
  159. [159]
    Impact of maternal factors, environmental factors, and race on ...
    The incidence of NEC in extremely premature infants is 9%3 and it incurs an economic burden between $500 million and $1 billion annually.
  160. [160]
    Establishing a nomogram for predicting necrotizing enterocolitis in ...
    The mainstay of treatment is surgery, but unfortunately, up to 20 %–50 % of neonates still die after surgery [3].
  161. [161]
    A Quality Improvement Initiative to Reduce Necrotizing Enterocolitis ...
    Nov 3, 2023 · Feeding human milk is the most effective strategy for protecting against NEC.7,8 Other preventive measures include standardized feeding regimens ...Missing: prophylactic | Show results with:prophylactic
  162. [162]
    Long term healthcare costs of infants who survived neonatal ...
    Aug 20, 2013 · The economic burden of NEC has been estimated to be approximately 500 million to 1 billion US dollars annually [1,10]. These estimates are ...
  163. [163]
    Healthcare Costs of Major Morbidities Associated with Prematurity in ...
    Surgical NEC, severe ROP, and severe BPD are the costliest morbidities, with median costs of $430,860, $413,825, and $399,495, respectively.
  164. [164]
    Frontiers | Economic evaluations of human milk for very preterm infants
    Four studies provided incremental costs (15, 16, 21, 32). Johnson et al. (21) found that NEC was associated with $66,015 greater costs per infant (P < 0.001), ...
  165. [165]
    Costs of Necrotizing Enterocolitis and Cost-Effectiveness of ...
    A net expected costs calculator was developed to compare the total NICU costs among extremely premature infants who were fed either a bovine milk-based HMF- ...